# US 2017/0283829 A1 · Sprr1a as a genetic target for treating neurodegenerative diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283829 A1
- Document ID: US20170283829A1
- Status: Published application
- Kind: A1
- Application number: 15/507,569
- Filed: 2015-08-27
- Published: 2017-10-05
- Earliest claimed: 2014-08-28
- Assignees: Board of Trustees of Michigan State University
- Applicants: Board of Trustees of Michigan State University
- Inventors: Jack W. Lipton; Nicholas Kanaan; Timothy Collier
- Web page: https://patentgrep.com/patent/US20170283829A1

## CPC

- C12N 15/86: Viral vectors
- A61K 35/30: Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
- A61K 38/04: Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof ({enzyme inhibitors A61K38/005;} gastrins {A61K38/2207}, somatostatins A61K38/31, melanotropins A61K38/34 {; protease inhibitors A61K38/55})
- A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 49/14: Peptides, e.g. proteins
- G01N 33/5008: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics}
- C12N 15/00: Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per se C12N1/00, C12N5/00, C12N7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H4/00; new animals per se A01K67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K48/00)
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- G01N 2800/2835: Movement disorders, e.g. Parkinson, Huntington, Tourette
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

This invention relates to the prevention and treatment of neurodegenerative diseases by administering compositions that increase the activity of a small proline-rich repeat 1 A protein (Sprr1A), or derivative thereof to the brain. Specifically, the compositions may comprise a nucleic acid molecule encoding a Sprr1A protein or a biologically-active portion thereof. The neurodegenerative disease may be Parkinson's Disease, Alzheimer's disease, amyotrophic lateral sclerosis, or traumatic brain injury.

## Claims

### Claim 1

A method for treating a neurodegenerative disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition, wherein said composition increases the activity of a small proline-rich repeat 1a protein (“Sprr1A”).

### Claim 2 (depends on 1)

The method of claim 1, wherein the neurodegenerative disease is Parkinson's Disease, Alzheimer's disease, amyotrophic lateral sclerosis, or traumatic brain injury.

### Claim 3 (depends on 1)

The method of claim 1, wherein the neurodegenerative disease is Parkinson's Disease.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition comprises a nucleic acid molecule.

### Claim 5 (depends on 4)

The method of claim 4, wherein said nucleic acid molecule encodes a Sprr1A protein, or a biologically-active portion thereof.

### Claim 6 (depends on 4)

The method of claim 4, wherein said composition comprises a virus.

### Claim 7 (depends on 6)

The method of claim 6, wherein the virus is an adeno-associated virus (“AAV”), adenovirus, herpes simplex virus, or lentivirus.

### Claim 8 (depends on 7)

The method of claim 7, wherein the virus is AAV.

### Claim 9 (depends on 8)

The method of claim 8, wherein the virus is AAV1.

### Claim 10 (depends on 6)

The method of claim 6, wherein the genome of said virus comprises said nucleic acid molecule.

### Claim 11 (depends on 4)

The method of claim 4, wherein said nucleic acid molecule comprises a nucleotide sequence that has at least 80% sequence homology with at least 36 consecutive nucleotides selected from the nucleotide sequence set forth in SEQ ID NO: 1.

### Claim 12 (depends on 4)

The method of claim 4, wherein said nucleic acid molecule comprises a nucleotide sequence that has at least 95% sequence homology with at least 36 consecutive nucleotides selected from the nucleotide sequence set forth in SEQ ID NO: 1.

### Claim 13 (depends on 4)

The method of claim 4, wherein said nucleic acid molecule comprises at least 36 consecutive nucleotides selected from the nucleotide sequence set forth in SEQ ID NO:1.

### Claim 14 (depends on 4)

The method of claim 4, wherein said nucleic acid molecule encodes an amino acid sequence that has at least 80% sequence homology with at least 12 consecutive amino acids selected from the amino acid sequence set forth in SEQ ID NO:2.

### Claim 15 (depends on 4)

The method of claim 4, wherein said nucleic acid molecule encodes an amino acid sequence that has at least 95% sequence homology with at least 12 consecutive amino acids selected from the amino acid sequence set forth in SEQ ID NO:2.

### Claim 16 (depends on 4)

The method of claim 4, wherein said nucleic acid molecule encodes at least 12 consecutive amino acids selected from the amino acid sequence set forth in SEQ ID NO:2.

### Claim 17 (depends on 1)

The method of claim 1, wherein administering comprises inserting the composition at a desired location.

### Claim 18 (depends on 17)

The method of claim 17, wherein the desired location is the brain.

### Claim 19 (depends on 18)

The method of claim 18, wherein the desired location is the substantia nigra, nigrostriatal system, hippocampus, medial temporal lobe, cerebral cortex, or spinal cord.

### Claim 20 (depends on 17)

The method of claim 17, wherein inserting comprises injecting the composition.

### Claim 21 (depends on 1)

The method of claim 1, wherein the subject is a mammal.

### Claim 22 (depends on 21)

The method of claim 21, wherein the subject is a primate, porcine, canine, ovine, or rodent.

### Claim 23 (depends on 21)

The method of claim 21, wherein the subject is a human.

### Claim 24

A method for treating Parkinson's Disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition, wherein:
the composition comprises a nucleic acid molecule;
the nucleic acid molecule encodes a small proline-rich repeat 1a protein (“Sprr1A”), or a biologically-active portion thereof; and
administering comprises inserting the composition into the brain.
